The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
US financial services company Morningstar has published its Biopharma Pipeline Report which provides a five-year outlook on key trends in the space, as well as an in-depth review of pipelines and major therapeutic areas. 29 September 2023
The UK pharma industry has responded to proposed changes to the statutory scheme for branded medicines, arguing against their implementation. 29 September 2023
US antibody-drug conjugate (ADC) specialist ImmunoGen (Nasdaq: IMGN) today announced findings from two subset analyses of the Phase III confirmatory MIRASOL trial (GOG 3045/ENGOT OV-55) evaluating the safety and efficacy of Elahere (mirvetuximab soravtansine-gynx). 28 September 2023
French contract development and manufacturing organization (CDMO) Cell-Easy, a specialist in cell therapies, has appointed Gisele Deblandre as chief scientific officer. 28 September 2023
Karuna Therapeutics has taken a significant step with its submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for KarXT (xanomeline-trospium), its ground-breaking product aiming to revolutionize the treatment of schizophrenia. 28 September 2023
Shares in New York-based stem cell specialist BrainStorm Cell Therapeutics have fallen around half ahead of the opening bell, after the firm provided a negative regulatory update. 28 September 2023
Having been collaborating for a decade, US RNA-targeted drug developer Ionis Pharmaceuticals and Swiss pharm giant Roche have signed a new agreement. 28 September 2023
Shares of US biotech Gritstone bio leapt almost 31% to $1.57 in pre-market trading on the news it had been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA). 28 September 2023
Seattle, USA-based clinical-stage biopharma Avalyn Pharmaceuticals has announced the closing of an oversubscribed $175 million Series C financing. 28 September 2023
Ophthalmic company Ocuphire Pharma, a specialist in retinal and refractive eye disorders, together with partner Viatris, have secured US approval for Ryzumvi (phentolamine). 27 September 2023
CRISPR genome-editing biopharma company Caribou Biosciences (Nasdaq: CRBU) dipped 3% to $4.76, after it revealed it has received notice from a unit of AbbVie (NYSE: ABBV) revealing that the US pharma major has elected to terminate the collaboration and license agreement, first signed in February 2021. 27 September 2023
Gilead Sciences has released a statement confirming it has stopped its ENHANCE-2 study of magrolimab in acute myeloid leukemia (AML). 27 September 2023
The US Food and Drug Administration has granted a new approval for US pharma giant Pfizer’s hematologic malignancies drug Bosulif (bosutinib). 27 September 2023
Adding to recent big-bucks deals with Merck & Co and Boehringer Ingelheim, Ginkgo Bioworks has now signed a collaboration deal with US pharma giant Pfizer focused on the discovery of RNA-based drug candidates. 27 September 2023
US biopharma Soleno Therapeutics saw its market capitalization leap five-fold yesterday, with the shares hitting $26.80, after it announced promising research results for its lead pipeline candidate, which has encountered previous setbacks. 27 September 2023
A report from industry analyst GlobalData finds that a range of new generic products in idiopathic pulmonary fibrosis (IPF) will likely shake up the market in coming years. 27 September 2023